protein

NLRP3

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about NLRP3: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

4753Connections

28Hypotheses

18Analyses

50Outgoing

50Incoming

5Experiments

20Debates

Summary

NLRP3 is a protein involved in neurodegeneration research. Key relationships include: activates, interacts with, associated with. Associated with AD, ALI, ALS. Connected to 1473 entities in the SciDEX knowledge graph.

View on Wiki →

AI-generated illustration · click image to enlarge

Regenerate portrait ↻

🔬 Protein Info

Gene Symbol	NLRP3
Protein Type	Signaling Protein
Target Class	Signaling Protein
Function	In the healthy nervous system, NLRP3: - Provides innate immune surveillance - Responds to pathogen-associated molecular patterns (PAMPs) - Initiates inflammatory responses to cellular stress - Facilit
Mechanism of Action	Small molecule inhibitors targeting NLRP3 inflammasome assembly or activation
Subcellular Localization	</th><td>Cytoplasm, inflammasome complex</td></tr>
Druggability	Medium (0.51)
Clinical Stage	Approved
Molecular Weight	118 kDa
Pathways	Adaptive Immunity, Ampk Signaling, Amyloid, Apoptosis, Autophagy
UniProt ID	A0A7I2R3P8
GeneCards	NLRP3
Human Protein Atlas	NLRP3
PYD (N-terminal)	Pyrin domain for homotypic interactions with ASC
NACHT	Central nucleotide-binding domain responsible for oligomerization and ATP hydrolysis
Associated Diseases	acute gouty arthritis, AD, Aging, ALI, Als
Known Drugs/Compounds	1,25(OH)2D, 1-deoxysphingolipids, Ams-17, Asiaticoside, Aucubin, Berberine
Interactions	ABCA1, ABCA7, ABCD3, ACE2, ACHE, acid sphingomyelinase
SciDEX Target	View Target Profile (8 clinical trials)
SciDEX Hypotheses	NLRP3/Mitophagy Coupling Modulation NLRP3 Inflammasome Inhibition Prevents Synapse Los Intermittent HBOT (2.0 ATA, 60 min, 3x/week) suppr (+5 more)
KG Connections	4752 knowledge graph edges
Databases	GeneCards NCBI Gene HPA STRING

🧬 3D Structure Comparison — NLRP3 Experimental (PDB) vs Predicted (AlphaFold) — click to expand

📄 Experimental Structure

7PZC — X-ray / Cryo-EM

🔮 AI Predicted Structure

Q96P20 — AlphaFold

Left: Experimental structure from RCSB PDB | Right: AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    subgraph Pathology["Pathology"]
        NLRP3["NLRP3"] -->|"associated with"| Inflammation["Inflammation"]
        TNF["TNF"] -->|"associated with"| NLRP3["NLRP3"]
        APOPTOSIS["APOPTOSIS"] -->|"associated with"| NLRP3["NLRP3"]
        AMYLOID["AMYLOID"] -->|"associated with"| NLRP3["NLRP3"]
        ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"] -->|"associated with"| NLRP3["NLRP3"]
    end
    subgraph Signaling["Signaling"]
        NLRP3["NLRP3"] -->|"activates"| Inflammasome["Inflammasome"]
        NLRP3["NLRP3"] -.->|"inhibits"| Inflammation_1["Inflammation"]
        NLRP3["NLRP3"] -.->|"inhibits"| Als["Als"]
        NLRP3["NLRP3"] -.->|"inhibits"| Inflammasome_2["Inflammasome"]
        NLRP3["NLRP3"] -->|"activates"| Inflammation_3["Inflammation"]
        NLRP3["NLRP3"] -->|"activates"| Autophagy["Autophagy"]
        NLRP3["NLRP3"] -->|"activates"| Als_4["Als"]
        NLRP3["NLRP3"] -->|"activates"| Neuroinflammation["Neuroinflammation"]
        MICROGLIA["MICROGLIA"] -->|"activates"| NLRP3["NLRP3"]
        ROS["ROS"] -->|"activates"| NLRP3["NLRP3"]
    end
    style NLRP3 fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0,font-weight:bold
    style Inflammation fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Inflammasome fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Inflammation_1 fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Als fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Inflammasome_2 fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Inflammation_3 fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Autophagy fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Als_4 fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Neuroinflammation fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style TNF fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style APOPTOSIS fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style AMYLOID fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style MICROGLIA fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style ALZHEIMER_S_DISEASE fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style ROS fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0

Outgoing (2656)

Target	Relation	Type	Str
Inflammasome	activates	pathway	1.00
NF-ΚB	activates	gene	1.00
Inflammation	associated_with	disease	1.00
Pyroptosis	activates	pathway	1.00
Nf-Κb	activates	pathway	1.00
Immune Response	activates	pathway	1.00
TNF	inhibits	gene	1.00
INFLAMMATION	activates	gene	1.00
UBIQUITIN	activates	gene	1.00
Als	activates	disease	1.00
MITOCHONDRIA	activates	gene	1.00
ALZHEIMER	activates	gene	1.00
OXIDATIVE STRESS	activates	gene	1.00
Neuroinflammation	activates	disease	1.00
IL-6	inhibits	gene	1.00
ASC	activates	protein	1.00
MICROGLIA	activates	gene	1.00
NEUROINFLAMMATION	activates	gene	1.00
APOPTOSIS	activates	gene	1.00
Inflammasome	inhibits	pathway	1.00
Autophagy	activates	pathway	1.00
Inflammation	regulates	disease	1.00
Als	inhibits	disease	1.00
CYTOKINES	activates	gene	1.00
MITOPHAGY	activates	gene	1.00
Inflammation	inhibits	disease	1.00
Inflammation	activates	disease	1.00
INFLAMMATION	regulates	gene	1.00
Inflammasome	regulates	pathway	1.00
INFLAMMATION	inhibits	gene	1.00
Mitophagy	activates	pathway	1.00
AUTOPHAGY	activates	gene	1.00
Neuroinflammation	inhibits	disease	1.00
Alzheimer	activates	disease	1.00
Apoptosis	activates	pathway	1.00
PYROPTOSIS	activates	gene	1.00
Oxidative Stress	activates	pathway	1.00
ALZHEIMER'S DISEASE	activates	gene	1.00
Mapk	activates	pathway	1.00
TNF-Α	inhibits	gene	1.00
CGAS	activates	gene	1.00
CYTOKINES	inhibits	gene	1.00
Nf-Κb	inhibits	pathway	1.00
inflammasome	involved_in	pathway	0.95
Cardiovascular	therapeutic_target	disease	0.95
IL-1β	upstream_of	protein	0.95
Als	therapeutic_target	disease	0.95
Aging	activates	disease	0.95
Parkinson'S Disease	involved_in	disease	0.95
NLRP3 Inflammasome	component_of	pathway	0.95

Incoming (2097)

Source	Relation	Type	Str
H3	indirectly_suppresses	hypothesis	0.00
IL-1B	associated_with	gene	1.00
NF-KB	associated_with	protein	1.00
PARKINSON'S DISEASE	associated_with	disease	1.00
TNF	associated_with	gene	1.00
AMYLOID	associated_with	gene	1.00
APOPTOSIS	associated_with	gene	1.00
ROS	activates	gene	1.00
ALZHEIMER'S DISEASE	associated_with	gene	1.00
MICROGLIA	activates	gene	1.00
IL-6	associated_with	gene	1.00
NEUROINFLAMMATION	activates	gene	0.98
USP22	inhibits	protein	0.95
Berberine	inhibits	compound	0.95
Microglia	expressed_in	cell_type	0.95
Ams-17	inhibits	compound	0.95
Irisin	inhibits	protein	0.95
AUTOPHAGY	inhibits	process	0.95
sevoflurane	activates	drug	0.95
Kaempferol	inhibits	compound	0.95
P62	degrades	protein	0.95
Pterostilbene	binds	compound	0.95
Qingqi Liangying Formula	inhibits	drug	0.95
Damps	activates	compound	0.95
PCBMA-TAPP	activates	compound	0.95
XHP	activates	drug	0.95
Litebamine	inhibits	compound	0.95
Pterostilbene	inhibits	compound	0.95
Aβ1-42	activates	biomarker	0.95
TLR2	activates	gene	0.95
NLRP3 inflammasome inhibitors	inhibits	drug	0.93
Tnea Therapy	inhibits	drug	0.93
Alpha-Synuclein	activates	protein	0.93
AUTOPHAGY	regulates	entity	0.92
NF-κB	upstream_of	pathway	0.92
ARRB2	interacts_with	protein	0.92
Cyclosporine A	upregulates	drug	0.92
TFEB	promotes	protein	0.92
Cerebral Ischemia-Reperfusion Injury	upregulates	disease	0.92
Hypoxic-Ischemic Brain Injury	upregulates	disease	0.91
ARRB2	modulates	protein	0.91
Aucubin	inhibits	compound	0.90
SCAP-SREBP2	activates	complex	0.90
Qingqi Liangying formula	inhibits	drug	0.90
Ginsenoside Re	inhibits	compound	0.90
Autophagy	regulates	process	0.90
NOD-like receptor signaling pathway	involved_in	pathway	0.90
CGAS	co_mentioned_with	gene	0.90
SDA-2026-04-01-gap-20260401-225155	targets	analysis	0.90
α7nAchR	inactivates	protein	0.90

Targeting Hypotheses (28)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming	0.907	neurodegeneration	What are the mechanisms by which gut mic
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S	0.822	neurodegeneration	What are the mechanisms by which gut mic
NLRP3 Inhibition (H7): Downstream Inflammatory Reversal	0.780	neurodegeneration	Does restoring neuronal AMPK activity re
NLRP3 Inflammasome Lock Perpetuates Senescence-Associated In	0.720	neurodegeneration	What molecular mechanisms drive microgli
NLRP3/Mitophagy Coupling Modulation	0.681	Neuroinflammation	Immune atlas neuroinflammation analysis

C1Q-Triggered NLRP3 Inflammasome Assembly in Plaque Macropha	0.631	neuroinflammation	What are the specific molecular mechanis
Galectin-3 deletion attenuates NLRP3 inflammasome activation	0.625	neuroscience	Lysosomal dysfunction and cathepsin leak
NLRP3 Inflammasome Priming Converts SCFA-Sensitive Pyroptosi	0.620	neurodegeneration	How does gut microbiome dysbiosis contri
Selective cathepsin B inhibition prevents cathepsin leakage-	0.620	neuroscience	Lysosomal dysfunction and cathepsin leak
LRP1/NLRP3/IL-1β Cascade Links Aβ Endocytosis to Inflammasom	0.617	neurodegeneration	How do perivascular cells specifically r
The most realistic translational use of physiological SCFAs	0.610	neurodegeneration	Do physiological concentrations of SCFAs
NLRP3 Inflammasome Inhibition Prevents Synapse Loss via IL-1	0.610	neurodegeneration	Test Preregistration Analysis
Intermittent HBOT (2.0 ATA, 60 min, 3x/week) suppresses NLRP	0.590	neurodegeneration	What are the optimal oxygen pressure, du
LAMP-2 replacement therapy prevents lysosomal membrane perme	0.580	neuroscience	Lysosomal dysfunction and cathepsin leak
CX3CR1-Negative Trem2-High Microglial Subset Mediates Female	0.570	neuroinflammation	How do regional, age, and sex-dependent
NLRP3 Inflammasome Chromatin Priming Through H3K27ac Accumul	0.566	developmental neurobiology	Do perinatal immune challenges create pe
NLRP3 Inflammasome Blockade as Upstream Intervention to Prev	0.566	neurodegeneration	Why have numerous phase 3 clinical trial
P2X7R PET Imaging for NLRP3 Inflammasome-Associated Priming	0.563	biomarkers	What biomarkers can reliably detect micr
Temporal NLRP3 Inhibition During SPP1-Driven Microglial Acti	0.551	neuroinflammation	What molecular mechanisms mediate SPP1-i
Physiological SCFAs may worsen alpha-synuclein pathology thr	0.550	neurodegeneration	Do physiological concentrations of SCFAs
Temporal NLRP3 Inhibition via SPP1-Mediated Mitophagy Enhanc	0.496	neuroinflammation	What molecular mechanisms mediate SPP1-i
TFEB-Mediated Lysosomal Biogenesis Enhancement for NLRP3 Inf	0.485	Neuroinflammation	Immune atlas neuroinflammation analysis
Sub-antidepressant Doses Suppress NLRP3 Inflammasome via P2X	0.465	-	What is the minimum effective dose of tr
Compensatory Cytokine Network Activation	0.455	clinical neurology	Why do systemic anti-inflammatory drugs
STING-Mediated NLRP3 Inflammasome Priming in ALS Microglia	0.380	Neuroinflammation	Immune atlas neuroinflammation analysis
NLRP3/Autophagy Flux Enhancement in Astrocytes	0.380	Neuroinflammation	Immune atlas neuroinflammation analysis
Circulating hs-CRP as Disease-Modifying Target via Astrocyti	0.380	immunomics	Systemic immune profiling in neurodegene
NLRP3 Inflammasome Suppression via Selective Caspase-1 Inhib	0.105	neurodegeneration	Neuroinflammation Biomarker Panel for Ea

Mentioning Analyses (18)

Scientific analyses that reference this entity

What is the minimum effective dose of trazodone required for disease-modifying e

neurodegeneration | 2026-04-26 | 7 hypotheses Top: 0.605

Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically re

neurodegeneration | 2026-04-12 | 2 hypotheses Top: 0.682

Why have numerous phase 3 clinical trials failed despite advances in understandi

neurodegeneration | 2026-04-12 | 1 hypotheses Top: 0.566

Does reduced Prevotellaceae abundance cause PD pathology or result from it?

neurodegeneration | 2026-04-11 | 0 hypotheses

Why do systemic anti-inflammatory drugs fail in AD despite cardiovascular effica

clinical neurology | 2026-04-08 | 7 hypotheses Top: 0.455

Experiments (5)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Molecular characterization of RBG-NLRP3 binding interaction	exploratory	atherosclerosis	0.900	0.00	purified proteins and molecula	proposed	N/A
Leukocyte gene expression analysis in COVID-19 patients	exploratory	COVID-19	0.900	0.00	human leukocytes from COVID-19	proposed	N/A
RBG effects on macrophage polarization and foam cell formation	exploratory	atherosclerosis	0.850	0.00	primary macrophages	proposed	N/A
Transcriptomic analysis of RBG effects on inflammatory gene expression	exploratory	atherosclerosis	0.800	0.00	ApoE-/- mice and cell cultures	proposed	N/A
NLRP3 Inflammasome Validation Study in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$5,460,000

Related Papers (10)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025
Inhibition of autophagy in microglia and macrophages exacerbates innate immune r [PMID:36652438]	Hegdekar N, Sarkar C, Bustos S, Ritzel R	Autophagy	2023
Parkin regulates microglial NLRP3 and represses neurodegeneration in Parkinson's [PMID:37029500]	Yan YQ, Zheng R, Liu Y, Ruan Y, Lin ZH,	Aging cell	2023
Microglial NLRP3 inflammasome activates neurotoxic astrocytes in depression-like [PMID:36288697]	Li S, Fang Y, Zhang Y, Song M, Zhang X,	Cell reports	2022
Biomarker of Neuroinflammation in Parkinson's Disease. [PMID:35456966]	Liu TW, Chen CM, Chang KH	Int J Mol Sci	2022
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554]	Marogianni C, Sokratous M, Dardiotis E,	International journal of molec	2020
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554]	Marogianni C, Sokratous M, Dardiotis E,	International journal of molec	2020
NLRP3 inflammasome activation drives tau pathology. [PMID:31748742]	["Ising C", "Venegas C", "Zhang S", "Sch	Nature	2019
Multiple Sclerosis Pathology. [PMID:29358320]	Lassmann H	Cold Spring Harbor perspective	2018

Debates (20)

Multi-agent debates referencing this entity

Extended debate: CYP46A1 Overexpression Gene Therapy

closed · Rounds: 6 · Score: 0.95 · 2026-04-27

Extended debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 6 · Score: 0.95 · 2026-04-27

Hypothesis debate: Membrane Cholesterol Gradient Modulators

closed · Rounds: 4 · Score: 0.50 · 2026-04-27

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.44 · 2026-04-27

Hypothesis debate: Microbial Inflammasome Priming Prevention

closed · Rounds: 4 · Score: 0.48 · 2026-04-27

Hypothesis debate: Selective Acid Sphingomyelinase Modulation Therapy

closed · Rounds: 4 · Score: 0.40 · 2026-04-27

Hypothesis debate: CYP46A1 Overexpression Gene Therapy

closed · Rounds: 4 · Score: 0.40 · 2026-04-27

What is the minimum effective dose of trazodone required for disease-modifying e

closed · Rounds: 4 · Score: 1.00 · 2026-04-26

Hypothesis debate: SASP Modulation Rather Than Cell Elimination

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Related Research

Hypotheses and analyses mentioning NLRP3 in their description or question text

NLRP3

Understanding Entity Pages

Summary

Wiki Pages (21)

NLRP3 (NLR Family Pyrin Domain Containing 3)

NLRP3 Inflammasome Activation Pathway in Neurodegeneration

NLRP3 Inflammasome Hypothesis in Parkinson's Disease

NLRP3 Inflammasome Pathway in Neurodegeneration

NLRP3 Senomorphic Cycling Therapy

NLRP3 Inflammasome Inhibitors for Parkinson's Disease

NLRP3-Coupled Senomorphic Cycling Therapy

NLRP3 Inflammasome Inhibitors for Neurodegenerative Diseases

NLRP3 Inhibitors for Neurodegeneration

NLRP3 Inflammasome Pathway in Alzheimer's Disease

NLRP3 Inflammasome Modulation for Parkinson's Disease

NLRP3 Inflammasome-Activated Microglia

Innate Immune Reprogramming: NLRP3 + CD47 Checkpoint Blockade

NLRP3 Inflammasome Therapeutics Investment Landscape

NLRP3 Inflammasome

CNS-Selective NLRP3 Inflammasome Inhibitor

NLRP3 Inflammasome Validation Study in Parkinson's Disease

NLRP3 Inflammasome Pathway in Neurodegeneration

NLRP3 Inflammasome Inhibitors

NLRP3 Protein

NLRP3 Inhibitors in Parkinson's Disease: Research and Clinical Development

Pathway Diagram

Outgoing (2656)

Incoming (2097)

Targeting Hypotheses (28)

Mentioning Analyses (18)

What is the minimum effective dose of trazodone required for disease-modifying e

Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically re

Why have numerous phase 3 clinical trials failed despite advances in understandi

Does reduced Prevotellaceae abundance cause PD pathology or result from it?

Why do systemic anti-inflammatory drugs fail in AD despite cardiovascular effica

Can circadian interventions reverse microglial priming independent of sleep disr

Lysosomal dysfunction and cathepsin leakage in Alzheimer disease progression

Senescent cell clearance as neurodegeneration therapy

Which cell types show the most significant expression changes for neurodegenerat

CRISPR-based therapeutic approaches for neurodegenerative diseases

Immune atlas neuroinflammation analysis in neurodegeneration

SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas

Synaptic pruning by microglia in neurodegeneration

Synaptic pruning by microglia in early AD

4R-tau strain-specific spreading patterns in PSP vs CBD

Lipid raft composition changes in synaptic neurodegeneration

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

Experiments (5)

Related Papers (10)

Debates (20)

Extended debate: CYP46A1 Overexpression Gene Therapy

Extended debate: Metabolic Reprogramming to Reverse Senescence

Hypothesis debate: Membrane Cholesterol Gradient Modulators

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

Hypothesis debate: Microbial Inflammasome Priming Prevention

Hypothesis debate: Selective Acid Sphingomyelinase Modulation Therapy

Hypothesis debate: CYP46A1 Overexpression Gene Therapy

What is the minimum effective dose of trazodone required for disease-modifying e

Hypothesis debate: SASP Modulation Rather Than Cell Elimination

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

Related Research

C1Q-Triggered NLRP3 Inflammasome Assembly in Plaque Macrophages

Galectin-3 deletion attenuates NLRP3 inflammasome activation downstream of lysos

NLRP3 Inflammasome Priming Converts SCFA-Sensitive Pyroptosis into Chronic IL-1β

Selective cathepsin B inhibition prevents cathepsin leakage-mediated NLRP3 infla

LRP1/NLRP3/IL-1β Cascade Links Aβ Endocytosis to Inflammasome Activation and SPP

The most realistic translational use of physiological SCFAs is as an adjunct to

NLRP3 Inflammasome Inhibition Prevents Synapse Loss via IL-1β Suppression

Intermittent HBOT (2.0 ATA, 60 min, 3x/week) suppresses NLRP3 inflammasome and s

LAMP-2 replacement therapy prevents lysosomal membrane permeabilization and down

CX3CR1-Negative Trem2-High Microglial Subset Mediates Female Resilience via Estr

NLRP3 Inflammasome Chromatin Priming Through H3K27ac Accumulation

NLRP3 Inflammasome Blockade as Upstream Intervention to Prevent SASP Amplificati

P2X7R PET Imaging for NLRP3 Inflammasome-Associated Priming

Temporal NLRP3 Inhibition During SPP1-Driven Microglial Activation Windows

Physiological SCFAs may worsen alpha-synuclein pathology through FFAR2/GPR43-NLR